MARKET

GERN

GERN

Geron
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.790
-0.020
-1.11%
After Hours: 1.770 -0.02 -1.12% 19:58 02/26 EST
OPEN
1.820
PREV CLOSE
1.810
HIGH
1.850
LOW
1.730
VOLUME
3.17M
TURNOVER
--
52 WEEK HIGH
2.400
52 WEEK LOW
0.7500
MARKET CAP
555.75M
P/E (TTM)
-5.0594
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Best Penny Stocks To Buy Today? 4 Biotech Stocks To Watch Now
Feb 24, 2021 (Penny Stocks via COMTEX) -- Can These 4 Penny Stocks Reach New Highs in 2021? This year has already gotten off to a great start for penny...
Penny Stocks · 4d ago
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 431,600 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the ...
Business Wire · 02/18 21:45
Global Vaccine, Insulin and Stem Cell Market Size 2021 Company Overview, Growth and Forecast By 2025 Latest Research Report by Industry Research Co
The Express Wire · 02/08 09:33
Is Geron (NASDAQ:GERN) Weighed On By Its Debt Load?
Simply Wall St. · 02/07 08:54
8-K: GERON CORP
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/06 02:07
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 120,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the ...
Business Wire · 01/21 21:45
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire · 01/21 21:45
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 120,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the ...
BusinessWire · 01/21 21:45
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GERN. Analyze the recent business situations of Geron through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GERN stock price target is 4.000 with a high estimate of 7.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 222
Institutional Holdings: 177.87M
% Owned: 57.29%
Shares Outstanding: 310.47M
TypeInstitutionsShares
Increased
54
10.73M
New
28
-204.83K
Decreased
35
7.57M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.06%
Pharmaceuticals & Medical Research
-0.68%
Key Executives
Chairman/President/Chief Executive Officer/Director
John Scarlett
Chief Financial Officer/Executive Vice President - Finance/Treasurer
Olivia Bloom
Chief Operating Officer/Executive Vice President
Andrew Grethlein
Executive Vice President/Secretary
Stephen Rosenfield
Vice President
Israel Gutierrez
Executive Vice President
Anil Kapur
Executive Vice President
Melissa Kelly Behrs
Executive Vice President
Aleksandra Rizo
Lead Director/Independent Director
Karin Eastham
Vice President/Director of Human Resources
Shannon Odam
Independent Director
Dawn Bir
Vice President
Sharo McBain
Independent Director
V. Bryan Lawlis
Vice President - Business Development
Lynn Bodarky
Independent Director
Susan Molineaux
Independent Director
Elizabeth O'Farrell
Independent Director
Robert Spiegel
  • Dividends
  • Splits
  • Insider Activity
No Data
About GERN
Geron Corporation (Geron) is a late-stage clinical biopharmaceutical company, which is focused on development and commercialization of imetelstat, a therapeutic for hematologic myeloid malignancies. The Company operates through a single segment, which is engaged in the development therapeutic products for oncology. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. The clinical studies of imetelstat includes IMerge, a Phase II/III trial in lower risk myelodysplastic syndromes (MDS) and IMbark, a Phase II trial in Intermediate- II or High-risk myelofibrosis.

Webull offers kinds of Geron Corporation stock information, including NASDAQ:GERN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GERN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GERN stock methods without spending real money on the virtual paper trading platform.